ABSTRACT
Cardiovascular disease is one of the main diseases that endanger human life and health, and heart failure often occurs when the cardiovascular disease develops to the end-stage. Heart transplantation is the most effective treatment. However, there has always been a shortage of living heart organs. With the development of regenerative medicine, researchers have turned to bioprinting technology that can build tissues and organs in vitro. A large number of relevant literature on three-dimensional (3D) bioprinted hearts were searched and screened in Google Scholar. 3D bioprinting technology can accurately print biomaterials containing living cells into 3D functional living tissues, providing a feasible solution to the shortage of transplantable organs. As one of the most important organs in the human body, the research on 3D bioprinting of the heart has currently become a hot topic. This paper briefly overviews 3D bioprinting technology and the progress in bioprinting cardiac tissue. It is believed that in the future, bio-printed hearts will become a reality, making a new way of providing artificial organs for heart transplantation.
ABSTRACT
Objective@#To explore the clinical efficacy of Yangxin-Fulv decoction combined with amiodarone hydrochloride in the treatment of dilated cardiomyopathy (DCM) complicated with ventricular arrhythmia (VA).@*Methods@#According to the random table method, 103 DCM patients with VA were divided into the control group (n=51) and the research group (n=52). The patients in the control group were given amiodarone hydrochloride orally on the basis of routine treatment, while the research group was given Yangxin-Fulv decoction on the basis of the control group. The treatment course of two groups was 3 months. The total number of ventricular premature beats, ventricular premature second rhythm, triple rhythm, short-term ventricular tachycardia,left ventricular ejection fraction (LVEF), left ventricular diastolic internal diameter (LVEDD), left ventricular end systolic diameter (LVESV) and left ventricular posterior wall thickness (LVPWT) were recorded by dynamic electrocardiogram analyzer. The Dynamic electrocardiogram was used to monitor QT interphase dispersion (QTd) and calibrate QT interphase dispersion (QTcd) and change of QTc interval. Clinical efficacy was evaluated and adverse reactions were recorded.@*Results@#The total effective rate of the research group was 88.5% while the control group was 62.8%, where the difference between two groups was statistically significant (χ2=6.106, P=0.014). After treatment, the total number of ventricular premature beats, ventricular premature second rhythm, triple rhythm, and short-term ventricular tachycardia in the research group were significantly lower than those in the control group (t=-7.005,-4.760,-16.111,-12.059, P<0.001). After treatment, the LVEF of the research group was significantly higher than that of the control group (t=4.024, P<0.01), while the LVEDD, LVESV and LVPWT of the research group were significantly lower than those of the control group (t=-3.913,-6.623,-5.719, P<0.001). After treatment, the changes of QTc interval (402.08 ± 30.14 ms vs. 421.08 ± 32.19 ms, t=-3.093), QTd (65.25 ± 5.63 ms vs. 72.18 ± 5.92 ms, t=-6.089) and QTcd (72.18 ± 10.56 ms vs. 80.53 ± 12.09 ms, t=-3.735) in the research group were significantly lower than those in the control group (P<0.01). During the treatment period, the incidence of adverse reactions in the control group was 7.8% (4/51) and in the research group was 5.8% (3/52). There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.175, P=0.676).@*Conclusions@#The Yangxin-Fulv decoction combined with amiodarone hydrochloride can improve the clinical symptoms and clinical efficacy of DCM patients with VA by inhibiting ventricular remodeling and arrhythmia.
ABSTRACT
Objective To explore the clinical efficacy of Yangxin-Fulv decoction combined with amiodarone hydrochloride in the treatment of dilated cardiomyopathy (DCM) complicated with ventricular arrhythmia (VA). Methods According to the random table method, 103 DCM patients with VA were divided into the control group (n=51) and the research group (n=52). The patients in the control group were given amiodarone hydrochloride orally on the basis of routine treatment, while the research group was given Yangxin-Fulv decoction on the basis of the control group. The treatment course of two groups was 3 months. The total number of ventricular premature beats, ventricular premature second rhythm, triple rhythm, short-term ventricular tachycardia,left ventricular ejection fraction (LVEF), left ventricular diastolic internal diameter (LVEDD), left ventricular end systolic diameter (LVESV) and left ventricular posterior wall thickness (LVPWT) were recorded by dynamic electrocardiogram analyzer. The Dynamic electrocardiogram was used to monitor QT interphase dispersion (QTd) and calibrate QT interphase dispersion (QTcd) and change of QTc interval. Clinical efficacy was evaluated and adverse reactions were recorded. Results The total effective rate of the research group was 88.5% while the control group was 62.8%, where the difference between two groups was statistically significant (χ2=6.106, P=0.014). After treatment, the total number of ventricular premature beats, ventricular premature second rhythm, triple rhythm, and short-term ventricular tachycardia in the research group were significantly lower than those in the control group (t=-7.005,-4.760,-16.111,-12.059, P<0.001). After treatment, the LVEF of the research group was significantly higher than that of the control group (t=4.024, P<0.01), while the LVEDD, LVESV and LVPWT of the research group were significantly lower than those of the control group (t=-3.913,-6.623,-5.719, P<0.001). After treatment, the changes of QTc interval (402.08 ± 30.14 ms vs. 421.08 ± 32.19 ms, t=-3.093), QTd (65.25 ± 5.63 ms vs. 72.18 ± 5.92 ms, t=-6.089) and QTcd (72.18 ± 10.56 ms vs. 80.53 ± 12.09 ms, t=-3.735) in the research group were significantly lower than those in the control group (P<0.01). During the treatment period, the incidence of adverse reactions in the control group was 7.8% (4/51) and in the research group was 5.8% (3/52). There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.175, P=0.676). Conclusions The Yangxin-Fulv decoction combined with amiodarone hydrochloride can improve the clinical symptoms and clinical efficacy of DCM patients with VA by inhibiting ventricular remodeling and arrhythmia.